Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
May 11 2022 - 8:15AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks, building on its deep-seated roots in hereditary
angioedema (HAE), today announced the appointment of Joan Schmidt,
J.D., to the newly created position of Chief Legal Officer,
effective June 1, 2022. In this role, she will lead all legal
activities, including compliance and governance, in support of
Pharvaris’ clinical drug development and commercialization
strategies.
Ms. Schmidt brings more than 20 years of leadership experience
in compliance, intellectual property, litigation, governance, and
people management within the biopharmaceutical industry. Most
recently, she served as the Executive Vice President, General
Counsel and Secretary at Arena Pharmaceuticals where, as a member
of the executive team, she developed and implemented company
strategy, and scaled and strengthened the legal, compliance, and
intellectual property functions prior to the company’s acquisition
by Pfizer in March 2022 for approximately $6.7 billion.
“Joan is a key new addition to our executive leadership team as
her legal expertise draws on extensive experience advising
biopharmaceutical companies that brought therapeutic products to
market,” said Berndt Modig, Chief Executive Officer of Pharvaris.
“Joan will be integrally involved in executing Pharvaris’ business
growth and strategic plans. We welcome her to our executive team
and look forward to her insights as we advance our oral
bradykinin-B2-receptor antagonists to people living with HAE.”
Ms. Schmidt commented, “I look forward to collaborating with the
team at Pharvaris as we advance our objectives to address critical
unmet needs for people living with HAE around the world. Pharvaris
is on an exciting journey, and I am looking forward to contributing
to the strategic direction of the company and strengthening its
legal and compliance functions as Pharvaris advances the clinical
and commercial pathways of its oral candidates.”
Prior to Arena, Ms. Schmidt served as General Counsel at DBV
Technologies and as U.S. General Counsel and Head of Human
Resources at Biotronik. Earlier, Ms. Schmidt had positions of
increasing responsibility at Novo Nordisk, both in the U.S. and
Europe, most recently as Corporate Vice President responsible for
global transactions, litigation, and trademarks. Ms. Schmidt earned
her J.D. from Elizabeth Haub School of Law at Pace University and
obtained a B.A. from the University of Connecticut.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE more effective and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
Forward-Looking StatementsThis press release
contains certain forward-looking statements that involve
substantial risks and uncertainties. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including, without
limitation, statements containing the words “believe,”
“anticipate,” “expect,” “estimate,” “may,” “could,” “should,”
“would,” “will,” “intend” and similar expressions. These
forward-looking statements are based on management’s current
expectations, are neither promises nor guarantees, and involve
known and unknown risks, uncertainties and other important factors
that may cause Pharvaris’ actual results, performance or
achievements to be materially different from its expectations
expressed or implied by the forward-looking statements. Such risks
include but are not limited to the following: the expected timing,
progress, or success of our clinical development programs,
especially for PHVS416 and PHVS719, which are in mid-stage clinical
trials; risks associated with the COVID-19 pandemic, which may
adversely impact our business, nonclinical studies, and clinical
trials; the timing of regulatory approvals; the value of our
ordinary shares; the timing, costs and other limitations involved
in obtaining regulatory approval for our product candidates PHVS416
and PHVS719, or any other product candidate that we may develop in
the future; our ability to establish commercial capabilities or
enter into agreements with third parties to market, sell, and
distribute our product candidates; our ability to compete in the
pharmaceutical industry and with competitive generic products; our
ability to market, commercialize and achieve market acceptance for
our product candidates; our ability to raise capital when needed
and on acceptable terms; regulatory developments in the United
States, the European Union and other jurisdictions; our ability to
protect our intellectual property and know-how and operate our
business without infringing the intellectual property rights or
regulatory exclusivity of others; our ability to manage negative
consequences from changes in applicable laws and regulations,
including tax laws; our ability to successfully remediate the
material weakness in our internal control over financial reporting
and to maintain an effective system of internal control over
financial reporting; changes in general market, political and
economic conditions, including as a result of the current conflict
between Russia and Ukraine; and the other factors described under
the headings “Cautionary Statement Regarding Forward-Looking
Statements” and “Item 3. Key Information—D. Risk Factors” in our
Annual Report on Form 20-F and other periodic filings with the
Securities and Exchange Commission.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. While Pharvaris may elect to update such
forward-looking statements at some point in the future, Pharvaris
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Pharvaris’ views as of any date
subsequent to the date of this press release.
ContactMaryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Sep 2023 to Sep 2024